Applied BioCode

Applied BioCode, Inc. has offices in the United States and Taiwan. The company currently employs over 60 people, focusing on R&D, instrument design, manufacturing, and U.S. commercialization. It develops, manufactures, and commercializes multiplex diagnostic testing products. Applied BioCode, Inc. has combined "digital barcodes" with immunochemical and molecular probes to create a new bio-inspired Barcode Magnetic Bead (BMB) technology. Microscopic BMBs, about the thickness of a human hair, are labeled with immunochemical or molecular probes, allowing for easy scanning of digital barcodes and accurate identification of a large number (4,906 barcodes) of biological targets without ambiguity.Applied BioCode, Inc.'s products focus on the $4.5 billion molecular diagnostics infectious disease market, with assays capable of detecting pathogens causing gastrointestinal infections, respiratory infections, and other high-value diseases. The company has received FDA approval for its BioCode® MDx-3000 system with a 17-plex Gastrointestinal Pathogen Panel (GPP) and a 17-plex Respiratory Pathogen Panel (RPP). The Gastrointestinal Pathogen Panel (GPP) has also obtained CE-Mark approval, allowing its use in European countries compliant with CE-Mark regulations. Applied BioCode, Inc. has also submitted its BioCode® SARS-CoV-2 Assay to the FDA for Emergency Use Authorization (EUA). Pre-EUA submission number: PEUA200355.Applied BioCode, Inc. collaborates with various diagnostic and pharmaceutical companies, with applications including infectious diseases, autoimmune diseases, allergies, gut microbiome analysis, and veterinary diagnostics.